https://www.pharmaradar360.com/article/lilly-to-present-initial-clinical-data-for-first-in-class-type-ii-jak2-inhibitor-1d944c5e76d37a00Pharma Surgeen2026-06-13T15:15:00.000ZLilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meetinghttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-f5b148e84160b8b3Pharma Surgeen2026-06-13T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-cfabc5d34119b944Pharma Surgeen2026-06-13T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-5b4f846043302578Pharma Surgeen2026-06-13T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-0585249cfeb9b326Pharma Surgeen2026-06-13T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-a7ec06942fd19887Pharma Surgeen2026-06-13T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-370dcb45b7eeb79dPharma Surgeen2026-06-13T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-e0a4c01d2ab7712bPharma Surgeen2026-06-13T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-581d62544b7f6479Pharma Surgeen2026-06-13T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-a8f26a913b32fb9fPharma Surgeen2026-06-13T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-278cde2649e20932Pharma Surgeen2026-06-13T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-9e10a47e8e877438Pharma Surgeen2026-06-13T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-41be6e441973a057Pharma Surgeen2026-06-13T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-9b4b2af10b2b3831Pharma Surgeen2026-06-13T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-ec8a24e4ca2d9775Pharma Surgeen2026-06-13T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/america-latina-llega-a-la-mesa-global-de-la-salud-yaneth-giha-es-elegida-vicepre-021de8a7b6ad807aPharma Surgeen2026-06-12T20:24:20.000ZAmérica Latina llega a la mesa global de la salud: Yaneth Giha es elegida Vicepresidenta del Consejo de IFPMAhttps://www.pharmaradar360.com/article/fda-approves-keytruda-pembrolizumab-and-keytruda-qlextm-pembrolizumab-and-berahy-51140963744f5e38Pharma Surgeen2026-06-12T20:10:00.000ZFDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)https://www.pharmaradar360.com/article/roche-receives-fda-approval-for-the-first-companion-diagnostic-to-assess-pten-pr-016dffe7d139921bPharma Surgeen2026-06-12T19:15:00.000ZRoche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancerhttps://www.pharmaradar360.com/article/oricell-brings-first-pivotal-stage-car-t-in-liver-cancer-cf1a4f821f299f3ePharma Surgeen2026-06-12T16:00:00.000ZOricell brings first pivotal-stage CAR T in liver cancerhttps://www.pharmaradar360.com/article/medtronic-completes-acquisition-of-scientia-vascular-seamlessly-integrating-acce-469fadaf5d680ba6Pharma Surgeen2026-06-12T15:00:00.000ZMedtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular carehttps://www.pharmaradar360.com/article/customizing-clinical-trial-content-for-boston-scientific-s-device-trials-790c6b3ef6210811Pharma Surgeen2026-06-12T14:39:53.000ZCustomizing Clinical Trial Content for Boston Scientific’s Device Trialshttps://www.pharmaradar360.com/article/decision-medical-devices-given-exceptional-use-authorisations-1da59e34d8e20cdePharma Surgeen2026-06-12T12:20:47.000ZDecision: Medical devices given exceptional use authorisationshttps://www.pharmaradar360.com/article/gsk-s-momelotinib-granted-orphan-drug-designations-in-the-us-and-eu-for-vexas-sy-1694c5206207a0bfPharma Surgeen2026-06-12T12:00:00.000ZGSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndromehttps://www.pharmaradar360.com/article/3f9e7a9025bdde1dPharma Surgeen2026-06-12T11:06:32.000ZΕξάρθρωση κυκλώματος παράνομης παραγωγής και εμπορίας φαρμάκωνhttps://www.pharmaradar360.com/article/abbvie-presents-new-data-at-eha-2026-congress-for-venclexta-venclyxto-venetoclax-3b4a161b7fe700dePharma Surgeen2026-06-12T07:00:00.000ZAbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Resultshttps://www.pharmaradar360.com/article/316121edb04a2d63Pharma Surgeen2026-06-12T06:30:00.000Zテセントリク、局所進行の食道がんにおける根治的化学放射線療法後の維持療法として適応拡大申請https://www.pharmaradar360.com/article/tecentriq-filed-for-additional-indication-as-maintenance-therapy-following-defin-1fa0a27aed6401bcPharma Surgeen2026-06-12T06:30:00.000ZTecentriq Filed for Additional Indication as Maintenance Therapy Following Definitive Chemoradiotherapy in Locally Advanced Esophageal Cancerhttps://www.pharmaradar360.com/article/engaging-the-immune-system-in-aml-a-new-frontier-in-the-pursuit-of-durable-outco-d02e217580fe003dPharma Surgeen2026-06-12T06:00:00.000ZEngaging the immune system in AML: A new frontier in the pursuit of durable outcomeshttps://www.pharmaradar360.com/article/yakkyokukata-pdg-march-2026-news-posted-37fe8e4d60071c6fPharma Surgeen2026-06-12T03:00:00.000Z[YAKKYOKUKATA]PDG March 2026 News postedhttps://www.pharmaradar360.com/article/best-ways-to-recover-from-jet-lag-d802bf93d731932cPharma Surgeen2026-06-12T00:00:00.000ZBest Ways to Recover From Jet Laghttps://www.pharmaradar360.com/article/on-behalf-of-respighi-bidco-s-p-a-offer-document-filed-with-consob-related-to-th-380b67a2582d061dPharma Surgeen2026-06-11T21:06:01.000ZOn behalf of Respighi BidCo S.p.A – Offer Document filed with CONSOB related to the voluntary totalitarian tender offer launched by Respighi BidCo S.p.A. on the ordinary shares of Recordati S.p.A.https://www.pharmaradar360.com/article/adial-pharmaceuticals-announces-acquisition-of-azora-therapeutics-and-up-to-64-m-f644b61d84c6ab12Pharma Surgeen2026-06-11T18:04:07.000ZAdial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financinghttps://www.pharmaradar360.com/article/why-do-i-pheel-this-way-episode-2-explores-social-life-support-and-self-advocacy-ceec7e4a3c55f8bbPharma Surgeen2026-06-11T17:48:35.000ZWhy Do I Pheel This Way? Episode 2 Explores Social Life, Support and Self-Advocacy for Teens with Phenylketonuriahttps://www.pharmaradar360.com/article/china-clears-alphamab-s-her2-bispecific-antibody-in-gastric-cancer-3f6eb07577d4a273Pharma Surgeen2026-06-11T16:00:00.000ZChina clears Alphamab’s HER2 bispecific antibody in gastric cancerhttps://www.pharmaradar360.com/article/przed-uzenie-dodatkowego-swiadectwa-ochronnego-mog-oby-dziesieciokrotnie-zwieksz-d578bc7567a1bb55Pharma Surgeen2026-06-11T15:09:31.000ZPrzedłużenie dodatkowego świadectwa ochronnego mogłoby dziesięciokrotnie zwiększyć inwestycje w badania i rozwój w Europiehttps://www.pharmaradar360.com/article/adial-pharmaceuticals-announces-acquisition-of-azora-therapeutics-and-up-to-64-m-ae0f2a5fc3d31b8fPharma Surgeen2026-06-11T14:45:37.000ZAdial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financinghttps://www.pharmaradar360.com/article/regulation-of-medical-devices-in-northern-ireland-d5934f909d804c54Pharma Surgeen2026-06-11T14:22:09.000ZRegulation of medical devices in Northern Irelandhttps://www.pharmaradar360.com/article/clinical-research-career-pathways-survey-c5cb0f498f105b4aPharma Surgeen2026-06-11T13:24:55.000ZClinical Research Career Pathways Surveyhttps://www.pharmaradar360.com/article/0-2-2026-5f90624d30545e24Pharma Surgeen2026-06-11T12:46:26.000ZΔιακήρυξη υπ. Αριθ. 0/2/2026 Ηλεκτρονικού Ανοικτού κάτω των Ορίων Διαγωνισμού για την Προμήθεια μονάδων αποθήκευσης και υπηρεσιών μετάπτωσηςhttps://www.pharmaradar360.com/article/regulation-of-ai-in-healthcare-10f88174ca8f7445Pharma Surgeen2026-06-11T11:00:01.000ZRegulation of AI in Healthcarehttps://www.pharmaradar360.com/article/relmada-therapeutics-appoints-cns-drug-development-veteran-michael-quirk-as-seni-205d264caf7d86c9Pharma Surgeen2026-06-11T11:00:00.000ZRelmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Programhttps://www.pharmaradar360.com/article/research-national-commission-into-the-regulation-of-ai-in-healthcare-research-en-21bb1db32095ead8Pharma Surgeen2026-06-11T11:00:00.000ZResearch: National Commission into the Regulation of AI in Healthcare: research, engagement and call for evidence findings